Sin categoría | 23 abril, 2026 - Escrito por: PR News

Genomics Services Market Set to Reach $24.0 Billion by 2033, Growing at 11.2% CAGR

PR Newswire

WILMINGTON, Del., April 23, 2026

Increasing prevalence of bleeding disorders, rising number of surgical procedures, aging population, and growing focus on interoperability are the major factors which drive global market growth.

WILMINGTON, Del., April 23, 2026 /PRNewswire/ — According to a new report published by Allied Market Research, the global Genomics Services Market was valued at $8.3 billion in 2023 and is projected to reach $24.0 billion by 2033, registering a robust compound annual growth rate (CAGR) of 11.2% from 2024 to 2033. The report, titled Genomics Services Market by Service Type, Application, End User, and Region: Global Opportunity Analysis and Industry Forecast, 2024 to 2033, provides a detailed assessment of prevailing trends, growth drivers, challenges, and competitive landscape shaping the future of this high-growth industry.

https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

Request Sample of the Report on Spinal Cord Stimulation Devices Market Forecast 2032 –https://www.alliedmarketresearch.com/request-sample/A324425

Market Size and Growth

The genomics services market is witnessing unprecedented expansion, underpinned by rapid progress in DNA sequencing technologies, bioinformatics, and precision medicine frameworks. Genomics services encompass a broad spectrum of offerings including whole-genome sequencing, exome sequencing, transcriptome sequencing, sample preparation, library preparation, bioinformatics analysis, and annotation services. As pharmaceutical and biotech companies increasingly shift toward outsourced genomics workflows to reduce cost and turnaround time, the demand for specialized genomics service providers continues to surge.

In 2024, the market is estimated to be valued at approximately $9.2 billion, progressing steadily toward the $24.0 billion milestone by 2033. This growth trajectory is supported by the declining cost of next-generation sequencing (NGS) platforms, which have made large-scale genomic analysis economically viable across academic, clinical, and commercial settings. Advances in AI-driven bioinformatics tools are also enabling faster and more accurate identification of novel biomarkers and therapeutic targets, creating a powerful multiplier effect on market growth.

Key Market Insights

The Allied Market Research report highlights several critical factors propelling the genomics services market forward:

Growing demand for personalized and precision medicine is driving healthcare providers and pharmaceutical companies to integrate genomic data into clinical decision-making, fueling the need for reliable, scalable genomics services.
Artificial intelligence and machine learning integration into genomics workflows is accelerating biomarker discovery, drug target identification, and genomic data interpretation, making AI-powered genomics platforms a key competitive differentiator.
The rapid expansion of gene therapy and cell therapy pipelines globally is generating substantial demand for high-throughput sequencing and companion diagnostic genomics services.
Government-backed population genomics initiatives in countries such as the United Kingdom (Genomics England), the United States (All of Us Research Program), and India (GenomeIndia) are generating massive datasets and creating long-term demand for genomics service providers.
Data privacy regulations, high operational standards, and the complexity of managing large genomic datasets remain key challenges for market participants, necessitating investment in secure, cloud-based, and regulatory-compliant platforms.

The outsourcing trend among pharmaceutical and biotech organizations is providing contract genomics service providers with significant growth opportunities, particularly in drug discovery, clinical trials, and companion diagnostics.

Want to Explore More, Connect to our Analyst –

https://www.alliedmarketresearch.com/connect-to-analyst/A324425

Market Segment Analysis

The genomics services market is segmented by service type, application, and end user, offering nuanced insights into where growth is concentrating.

By Service Type: The market spans sequencing services (whole-genome sequencing, exome sequencing, and transcriptome sequencing), data analysis and bioinformatics services, sample preparation services, library preparation services, and annotation services. Sequencing services constitute the largest revenue contributor, driven by falling per-genome sequencing costs and the accelerating clinical adoption of NGS platforms.

By Application: Key application segments include clinical research, diagnostics, drug discovery and development, agricultural genomics, microbiome studies, and forensic genomics. The clinical research segment commands the largest share, accounting for the majority of outsourced genomics spending, while the diagnostics application is emerging as one of the fastest-growing segments due to expanding use of genomic panels in oncology and rare disease diagnostics.

By End User: The primary end users of genomics services include pharmaceutical and biopharmaceutical companies, biotechnology firms, academic and government research institutions, contract research organizations (CROs), and hospitals and diagnostic laboratories. Pharmaceutical and biotech companies represent the dominant end-user segment, leveraging genomics services extensively across early-stage drug discovery, translational research, and clinical development.

Regional Insights

North America is the dominant regional market for genomics services, accounting for a substantial share of global revenue. The United States leads regional demand, supported by a mature biotech and pharmaceutical ecosystem, robust federal funding for genomics research, favorable regulatory frameworks, and the early adoption of precision medicine initiatives. The presence of leading genomics service companies, advanced research infrastructure, and a high density of academic medical centers further solidifies North America’s leading position.

Europe holds the second-largest share, driven by government-backed genomics programs across the United Kingdom, Germany, France, and the Netherlands. The European Union’s commitment to digital health and precision medicine, combined with increasing biotech investment, positions the region as a critical growth market through 2033.

Asia-Pacific is identified as the fastest-growing regional market in the Allied Market Research report. Expanding biotech research and development activity in China, India, Japan, and South Korea, coupled with government genomics initiatives and rising healthcare expenditure, is rapidly increasing regional demand. In particular, India’s GenomeIndia project and China’s continued investment in large-scale population sequencing are expected to be strong regional growth catalysts. The improving research infrastructure and growing talent pool across Southeast Asia are also attracting investments from global genomics service providers.

Latin America and the Middle East and Africa are emerging markets at earlier stages of genomics adoption, but represent meaningful long-term opportunities as healthcare infrastructure improves, and awareness of precision medicine expands.

For Purchase Related Queries/Enquiry –

https://www.alliedmarketresearch.com/purchase-enquiry/A324425

Key Players in the Genomics Services Market

The genomics services market is characterized by intense competition, with a mix of established multinational corporations, specialized genomics service providers, and emerging technology-driven startups. Leading players identified in the Allied Market Research report include:

Illumina, Inc. — a global leader in genome sequencing solutions, offering a broad portfolio of consumables, integrated systems, and analytical instruments for genetic analysis across research and clinical markets.
Thermo Fisher Scientific, Inc. — a leading provider of genomics reagents, library preparation kits, sequencing systems, and bioinformatics software, with a strong presence across pharmaceutical, biotech, and academic segments.
BGI Genomics Co., Ltd. — one of the world’s largest genomics organizations, offering comprehensive sequencing and bioinformatics services across clinical, research, and agricultural applications.
F. Hoffmann-La Roche Ltd. — leveraging its diagnostics and pharmaceutical expertise to deliver integrated genomics solutions for companion diagnostics and precision oncology.
Agilent Technologies, Inc. — providing target enrichment, library preparation, and bioinformatics tools that support high-throughput genomics workflows.
GENEWIZ (Azenta Life Sciences) — a specialized genomics CRO offering sequencing, synthesis, and bioinformatics services to global research customers.
Danaher Corporation — operating genomics capabilities through subsidiaries including Integrated DNA Technologies (IDT) and Cepheid, serving pharmaceutical and research markets.
QIAGEN N.V. — delivering sample and assay technologies that form the foundation of clinical and research genomics workflows worldwide.
Eurofins Scientific — a major genomics CRO offering sequencing and clinical testing services across pharmaceutical development and diagnostics.
Oxford Nanopore Technologies PLC — pioneering long-read, real-time sequencing platforms with applications in clinical research, infectious disease, and agricultural genomics.

These companies are investing in R and D, strategic partnerships, geographic expansion, and AI-powered analytics platforms to sustain competitive advantage in a rapidly evolving market.

Key Recent Industry Developments

The genomics services market has witnessed several notable developments that underscore the pace of innovation and competitive activity:

March 2025: Illumina announced the launch of the NovaSeq X platform, a next-generation sequencing system designed to significantly reduce the cost of whole-genome sequencing while tripling data throughput, targeting large-scale global genomics programs.
February 2025: Thermo Fisher Scientific completed its acquisition of Olink Proteomics, expanding its multi-omics capabilities and strengthening its biomarker discovery portfolio for translational research and clinical applications.
January 2025: BGI Genomics launched the MGISP-NEO, a portable next-generation sequencing system designed for rapid pathogen detection in mobile and resource-limited healthcare settings, targeting developing market adoption.
June 2024: Danaher Corporation launched an HIV sequencing panel to advance virology research, reflecting continued innovation in its NGS-based diagnostics portfolio.
July 2024: Thermo Fisher Scientific introduced a novel pre-transplant risk assessment assay for kidney transplant rejection, demonstrating the growing clinical application of genomics in transplant medicine.
2024: Integrated DNA Technologies (IDT) entered a strategic collaboration with Element Biosciences to develop streamlined NGS workflows, aimed at improving sequencing efficiency and reducing laboratory complexity for end users.

Explore AMR’s Extensive Ongoing Coverage on Life Science Industry:

Syphilis Immunoassay Diagnostics Market